Scholarlink

<p>Breast cancer survivors require continuing long-term care, which leads to substantial resource use and subsequently increased healthcare costs (HC), having an impact on both the individual and society. This paper aims to investigate the impact of a breast cancer diagnosis on monthly HC and out-of-pocket (OOP) costs among survivors. We apply an event study methodology using a two-part fixed-effect model. Data from the Australian Longitudinal Study of Women’s Health (2002-2017) is utilised, which is linked to extensive high-frequency administrative records from the Medicare Benefits Schedule, the Pharmaceutical Benefits Scheme, the Australian Cancer Database and the National Death Index. The findings reveal that a diagnosis leads to a persistent and substantial increase in total HC and OOP costs, with the largest increases occurring in the first six months. The effects’ duration and magnitude vary by the type of healthcare service and pharmaceuticals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Healthcare cost for non-hospital services and pharmaceuticals among breast cancer survivors: an event study

  • 期刊论文

  • 发表日期：

    2026年1月31日

查看全文
  • Aarushi Dhingra,
  • Brenda Gannon,
  • Terence C Cheng,
  • Luke Connelly,
  • Gita Mishra

摘要

Breast cancer survivors require continuing long-term care, which leads to substantial resource use and subsequently increased healthcare costs (HC), having an impact on both the individual and society. This paper aims to investigate the impact of a breast cancer diagnosis on monthly HC and out-of-pocket (OOP) costs among survivors. We apply an event study methodology using a two-part fixed-effect model. Data from the Australian Longitudinal Study of Women’s Health (2002-2017) is utilised, which is linked to extensive high-frequency administrative records from the Medicare Benefits Schedule, the Pharmaceutical Benefits Scheme, the Australian Cancer Database and the National Death Index. The findings reveal that a diagnosis leads to a persistent and substantial increase in total HC and OOP costs, with the largest increases occurring in the first six months. The effects’ duration and magnitude vary by the type of healthcare service and pharmaceuticals.